Maplight Therapeutics, INC. (MPLT) — 10-Q Filings
All 10-Q filings from Maplight Therapeutics, INC.. Browse 1 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (1)
-
MapLight's R&D Soars, IPO Fuels Future Clinical Trials
— Dec 4, 2025 Risk: medium
MapLight Therapeutics, Inc. (MPLT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $81.6 million, up from $56
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX